Compugen Ltd.

NASDAQ:CGEN

Biotechnology

Healthcare
$1.96 +0.50%

+$0.01 today

Market cap
$185.66M
Beta
2.74
P/E (TTM)
5.4
EPS (TTM)
$0.37
52W Low $1.30High $3.24

Volume 0.15M

Average 0.48M

Returns on capital

Compugen Ltd. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

34.4%

avg -41.0%

ROIC

23.2%

avg -36.6%

ROA

22.5%

avg -31.1%

Analysis

ROE is currently the strongest return metric at 34.4% versus its period average of -41.0%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Anat Cohen-Dayag

Executive ChairUSD 615.89K59100.00K0.11%

Michelle Mahler

Chief Medical OfficerUSD 535.49K—18.00K0.02%

Pierre Ferre

Chief Operating OfficerUSD 485.85K4970.00K0.07%

Eran Ophir

Chief Executive Officer, President & DirectorUSD 410.19K48200.00K0.21%

Zurit Levine

Senior Vice President of Business DevelopmentUSD 312.61K5824.00K0.03%

David Silberman

Chief Financial Officer—4226.00K0.03%

Eran Ben Dor

General Counsel & Corporate Secretary————

Dorit Amitay

Vice President of Human Resources—58——

Lindsey Trickett

Head of Investor Relations and Corporate Communications————

Rivka Schwartz

Vice President Research and Discovery————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jul 29, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

11

$118,278.69

Net Transaction Value

−$118,278.69

Net selling

Most Active

Levine Zurit

8 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Jul 9, 26

Levine Zurit

Direct

Sell$4.7K
Apr 24, 26

Ophir Eran

Direct

Sell$16K
Apr 24, 26

Levine Zurit

Direct

Sell$6.4K
Apr 14, 26

Levine Zurit

Direct

Sell$5.6K
Apr 14, 26

Ophir Eran

Direct

Sell$14.5K
Apr 10, 26

Levine Zurit

Direct

Sell$8K
Apr 8, 26

Levine Zurit

Direct

Sell$13K
Apr 7, 26

Levine Zurit

Direct

Sell$5.8K
Apr 1, 26

Ophir Eran

Direct

Sell$12.4K
Apr 1, 26

Levine Zurit

Direct

Sell$7.7K

1–10 of 11

Summary

Insiders reported 0 buys worth $0.00 and 11 sells worth $118,278.69 over the last 12 months. That adds up to net selling of $118,278.69. Levine Zurit was the most active insider with 8 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/A+113.3%
-13.1% (5yr)2 analysts
Net IncomeN/AN/AN/A
N/A2 analysts
EBITN/AN/AN/A
N/A2 analysts

Analysis

Recent growth has been strongest in Revenue at +113.3% over three years. Forward estimates point to Revenue at -13.1% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Compugen Ltd. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about CGEN's management, answered from reported figures.

Who manages CGEN?

Compugen Ltd. (CGEN) lists 10 active executives. The top listed executive is Anat Cohen-Dayag, Executive Chair.

Are CGEN insiders buying or selling?

Recent insider activity shows net buying of $1.16M.